THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF)
Clinical trials for THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF) explained in plain language.
Never miss a new study
Get alerted when new THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF) trials appear
Sign up with your email to follow new studies for THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Desperate patients gain access to promising drug through managed programs
Disease control AVAILABLEThis program provides access to the drug ruxolitinib (INC424) for patients with serious or life-threatening conditions like certain blood cancers, severe COVID-19, or graft-versus-host disease when no other treatments are available. It is for people who cannot join a clinical tri…
Matched conditions: THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF)
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New registry aims to unlock secrets of rare blood cancers
Knowledge-focused Recruiting nowThis study follows 5,000 adults with myeloproliferative neoplasms (MPNs) — rare blood cancers — to understand how symptoms change and how the disease progresses over years. Participants share their health records, insurance data, and regular surveys about how they feel. No new tr…
Matched conditions: THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF)
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated May 04, 2026 16:17 UTC